In other words, lower CD8+ lymphocyte counts and/or higher CD20+ lymphocyte counts are linked to the effectiveness of immunotargeted therapy in individuals with advanced or metastatic endometrial cancer. This evidence concerns the gene CD8A and endometrial cancer.